[Medical treatment of endometriosis].

La Revue du praticien · 1999 · vol. 49(3) , pp. 269–75 · PMID:10189795 · W2398983160
article OA: closed CC0 ⤵ 2 in-corpus citations
View on OpenAlex View on PubMed
AI-generated summary by claude@2026-06, 2026-06-09

Medical treatments for endometriosis, primarily hormonal, aim to induce a resting state in lesions, with progestins being cost-effective for pain and Gn-RH analogs potent for severe cases, though adhesions and sequelae are unresponsive.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Medical treatment of endometriosis has been applied since 40 years. Its rational is based upon the hormone-dependency of the endometriotic lesions inducing a resting status. Adhesions, endometriomas or fibrous sequellae do not respond to medical treatment. Its use in case of associated infertility is very limited. Numerous agents are available for clinical use. Progestins are efficient on pelvic pain, contra-indications, clinical and metabolic tolerance are linked to the hormonal activity of the molecules. They have a low cost. Newer pills deserve to be evaluated. Danazol has now few indications in regards to its clinical and metabolic side-effects. Gn-RH analogs bear a potent efficacy and a very low intrinsic toxicity. They are preferentially used in severe cases, in association with surgery and before an IVF. Add back therapy improves the clinical tolerance and reduces bone mass loss. Many parameters should be taken into account when selecting a specific modality.

My notes (saved in your browser only)

Condition tags

endometriosischronic_pelvic_paininfertility

MeSH descriptors

Endometriosis Bone Density Bone Density Contraindications Danazol Danazol Danazol Drug Costs Endometriosis Endometriosis Endometriosis Endometrium Endometrium Estrogen Antagonists Estrogen Antagonists Estrogen Antagonists Female Fertilization in Vitro Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (2)

Cited by (2)

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:10:29.640636+00:00
License: CC0 · commercial use OK